JEA BizDev Consulting, LLC®

Find your next opportunity.

HomeConnecting science. Creating value.PagesServicesExpertise across the BD value chainPagesAbout JohnExperience behind the partnershipsPagesOur approachFrom strategy to signed agreementPagesOpportunitiesExplore assets for partneringPagesTrack recordPartnerships and downloadable deal summariesPagesStart a conversationDiscuss an opportunity with JohnPagesMy cross-border dealsJEA reference library on Google DriveTransactionsCross-border deal libraryJEA reference library on Google DriveTransactionsDLL3 ADCOncology · IND Filing · DLL3AssetsHER2 Biparatopic ADCOncology · Phase 3 · HER2AssetsFRα Biparatopic ADCOncology · IND Filing · FRαAssetsCYP11B2 InhibitorCardiovascular · IND Filing · CYP11B2AssetsENPP1 InhibitorCardiovascular · IND Approved · ENPP1AssetsB7-H3 ADCOncology · Phase 1 · B7-H3AssetsATM InhibitorOncology · Phase 1 · ATMAssetsKAT6 InhibitorOncology · Phase 1 · KAT6A / KAT6BAssetsEGFR-ADCOncology · Phase 3 · EGFRAssetsNovaRock × Bionyra (2026)Exclusive license agreement for NBL-023, a novel anti–IL-25 monoclonal antibody, granting worldwide rights outside Greater China.TransactionsNovaRock × LigaChemBio (2026)Global out-licensing agreement for an ADC candidate targeting a novel oncology antigen.TransactionsCSPC × Radiance Biopharma (2025)$1,240 million strategic partnership for ROR1-ADC (SYS6005).TransactionsCSPC × Cipla (2025)$1,065 million strategic partnership for an Irinotecan Liposomal Injection product.TransactionsNovaRock × LigaChemBio (2025)Two global out-licensing agreements for novel antibodies.Transactions

LET’S CONNECT

Every partnership starts somewhere.

Tell us what you are working toward. We’ll start with your priorities and explore the right next step together.

01Let’s get acquainted

Fields marked * are required.

02The opportunity ahead

Complete your name, valid email, company, and priorities, then check the consent box to continue.